Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy

NCT05162066 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.

NCT NCT05162066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
Lead sponsor
BioCryst Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
February 18, 2022
Completion date
September 23, 2022
Enrollment
2 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

complement 3 glomerulopathy, immunoglobulin a nephropathy, membranous nephropathy